Navigation Links
Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for First Quarter Fiscal 2011
Date:11/11/2010

Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for First Quarter Fiscal... -- LAIYANG, China, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for First Quarter Fiscal 2011

 

LAIYANG, China, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that the Company will host a conference call at 10:00 a.m. Eastern Standard Time on Tuesday, November 16, 2010 to discuss financial results for the first quarter fiscal 2011 ended September 30, 2010.

The conference call will be hosted by Mr. Linxian Jin, CEO, and Ms. Elsa Sung, CFO, of Jiangbo.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 815-0215. International callers should dial +1 (706) 758-5465. The Conference ID for this call is 24282922.If you are unable to participate on the live call, a replay will be available for 14 days starting on Tuesday, November 16, 2010 at 11:00 a.m. Eastern Standard Time. To access the replay, dial (800) 642-1687, international callers dial (706) 645-9291. The Conference ID is 24282922.

About Jiangbo Pharmaceuticals, Inc.Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (www.jiangbopharma.com).

Safe Harbor StatementCertain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to execute its strategic plan. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.Contact: Jiangbo Pharmaceuticals, Inc.

CCG Investor Relations  Ms. Elsa Sung, CFO

Mr. Crocker Coulson, PresidentPhone: (954) 903-9378 ex 2

Phone: (646) 213-1915E-mail: elsasung@jiangbo.com

E-mail: crocker.coulson@ccgir.com  http://www.jiangbopharma.com

http://www.ccgirasia.com
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
2. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
4. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
6. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
7. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
8. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
9. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
10. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
11. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Vivify Health, the pioneer and market leader of remote ... significant patent for the advancement of healthcare delivery from ... health.  This landmark patent provides the company with broad ... position as the leader in remote care.  ... to apply consumer mobile devices, wireless biometrics, EMR integration ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Injectables Market and Increasing Usage of Complex Biologics during the Forecast ... ... USD 20 Billion in 2015 to around USD 26 Billion by ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Bill Howe ... industry in the coastal communities. After Tina Howe joined the team, the Bill Howe ... employees, honest services at affordable rates, and giving back to the San Diego community ...
Breaking Medicine News(10 mins):